Five Prime Therapeutics (FPRX) Misses Q1 EPS by 8c

Five Prime Therapeutics (NASDAQ: FPRX) reported Q1 EPS of ($0.63), $0.08 worse than the analyst estimate of ($0.55).

For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Dollar General (DG) Tops Q2 EPS by 48c, Beats on Revenue; Offers FY27 EPS Guidance
• Titan Machinery (TITN) Misses Q2 EPS by 5c ; Offers Guidance